| Prior therapies, n (%) |
AS (N = 187) |
PsA (N = 385) |
P-value (Chi-square test) |
Total (N = 572) |
|---|---|---|---|---|
| NSAIDs | 112 (59.9) | 96 (24.9) | <.0001 | 208 (36.4) |
| Other analgesics | 32 (17.1) | 31 (8.1) | 0.0012 | 63 (11.0) |
| DMARDs | 70 (37.4) | 280 (72.7) | – | 350 (61.2) |
| Methotrexate * | 40 (21.4) | 219 (56.9) | <.0001 | 259 (45.3) |
| Azathioprin * | 1 (0.5) | 4 (1.0) | 0.5434 | 5 (0.9) |
| Sulfasalazin * | 50 (26.7) | 66 (17.1) | 0.0074 | 116 (20.3) |
| Leflunomid * | 11 (5.9) | 110 (28.6) | <.0001 | 121 (21.2) |
| Cyclosporine * | 0 | 42 (10.9) | <.0001 | 42 (7.3) |
| Chloroquin/hydrochloroquin * | 2 (1.1) | 7 (1.8) | 0.4997 | 9 (1.6) |
| Gold compound * | 2 (1.1) | 4 (1.0) | 0.9732 | 6 (1.0) |
| Secukinumab #* | 37 (19.8) | 91 (23.6) | NA | 128 (22.4) |
| Other biologics | 120 (64.2) | 260 (67.5) | – | 380 (66.4) |
| Adalimumab * | 81 (43.3) | 164 (42.6) | 0.8707 | 245 (42.8) |
| Etanercept * | 73 (39.0) | 121 (31.4) | 0.0714 | 194 (33.9) |
| Infliximab * | 41 (21.9) | 42 (10.9) | 0.0004 | 83 (14.5) |
| Certolizumab pegol * | 38 (20.3) | 40 (10.4) | 0.0012 | 78 (13.6) |
| Golimumab * | 54 (28.9) | 65 (16.9) | 0.0009 | 119 (20.8) |
| Ustekinumab * | 1 (0.5) | 82 (21.3) | <.0001 | 83 (14.5) |
| Biosimilars | 2 (1.1) | 5 (1.3) | – | 7 (1.2) |
| Infliximab | 1 (0.5) | 5 (1.3) | 0.7421 | 6 (1.0) |
| Etanercept | 1 (0.5) | 0 | 0.1510 | 1 (0.2) |
| Others | 24 (12.8) | 73 (19.0) | – | 97 (17.0) |
| Apremilast | 0 | 24 (6.2) | 0.0005 | 24 (4.2) |